-
ACLA Comments on USCDI+ Laboratory Data Exchange
-
Statement of ACLA President to the Health Subcommittee of the House Energy & Commerce Committee
-
ACLA’s Comments on FDA’s Proposed Regulation of Laboratory Developed Tests as Medical Devices
-
ACLA Comments to Sen. Cassidy’s White Paper on AI
-
ACLA Submits Comments on CMS Medicare Physician Fee Schedule Proposed Rule
-
ACLA Response to Draft Local Coverage Determinations, Genetic Testing for Oncology
-
Appendix to ACLA Response to Draft Local Coverage Determinations, Genetic Testing for Oncology
-
Letter from Leading Cancer-Related Provider Groups and Patient Advocates on Genetic Testing for Oncology
-
ACLA Submits Comments on CMS Transitional Coverage For Emerging Technologies Notice
-
ACLA Submits Comments on CMS Pre-Exposure Prophylaxis (PrEP) Proposed NCD
